Cryosite Ltd. Stock Analysis CTE.AX

Cryosite Ltd. engages in the provision of long-term storage, supply chain logistics management of pharmaceutical products used in clinical trials and biological materials. The company is headquartered in Sydney, New South Wales and currently employs 25 full-time employees. The company went IPO on 2002-05-09. The firm manages the entire clinical trial supply chain from importation, receipt, specialized ambient, cold, frozen, and liquid nitrogen storage for temperature-sensitive products, distribution and reverse logistics management. Its segments include Ambient, Cold, and Frozen, Ultra Frozen and Cryogenic and Cord blood. The Ambient, Cold, and Frozen segment storages and distributes small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions. Ultra Frozen and Cryogenic is engaged in specialized handling of materials requiring Ultra-Frozen or Cryogenic conditions, including Advanced Therapy Medicinal Products (ATMPs), such as Cell and Gene Therapies (CGT), cell therapies, and others. The cord blood segment is engaged in storage of cord blood cell and tissue samples for personal or directed therapeutic use, maintained under validated chain-of-identity controls.